

- 4 Donders AR, van der Heijden GJ, Stijnen T, *et al.* Review: a gentle introduction to imputation of missing values. *J Clin Epidemiol* 2006; 59: 1087–1091.
- 5 Payton T, Girgenti D, Frenck RW, *et al.* Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States. *Pediatr Infect Dis J* 2013; 32: 871–880.
- 6 Gutiérrez Brito M, Thompson A, Girgenti D, *et al.* Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. *Rev Panam Salud Publica* 2013; 33: 414–421.
- 7 Wysocki J, Brzostek J, Szymański H, *et al.* Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. *Vaccine* 2015; 33: 1719–1725.
- 8 Vesikari T, Karvonen A, Korhonen T, *et al.* Immunogenicity of 10-valent pneumococcal nontypeable *Haemophilus influenzae* protein D conjugate vaccine when administered as catch-up vaccination to children 7 months to 5 years of age. *Pediatr Infect Dis J* 2011; 30: e130–e141.
- 9 Rivera-Olivero IA, Del Nopal B, Fuentes M, *et al.* Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases. *Vaccine* 2014; 32: 4006–4011.
- 10 Figueiredo CA, Barreto ML, Rodrigues LC, *et al.* Chronic intestinal helminth infections are associated with immune hyporesponsiveness and induction of a regulatory network. *Infect Immun* 2010; 78: 3160–3167.
- 11 Madhi SA, Violari A, Klugman KP, *et al.* Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by *Streptococcus pneumoniae* during the primary series of immunization. *Vaccine* 2011; 29: 6994–7001.
- 12 Strutton DR, Farkouh RA, Rubin JL, *et al.* Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. *BMC Infect Dis* 2012; 12: 175.
- 13 Andrews NJ, Waight PA, Burbidge P, *et al.* Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. *Lancet Infect Dis* 2014; 14: 839–846.
- 14 Castañeda E, Agudelo CI, Regueira M, *et al.* Laboratory-based surveillance of *Streptococcus pneumoniae* invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000–2005. *Pediatr Infect Dis J* 2009; 28: e265–e270.
- 15 Mubarak A, Ahmed MS, Upile N, *et al.* A dynamic relationship between mucosal T helper type 17 and regulatory T-cell populations in nasopharynx evolves with age and associates with the clearance of pneumococcal carriage in humans. *Clin Microbiol Infect* 2016; in press [DOI: 10.1016/j.cmi.2016.05.017].

Eur Respir J 2016; 48: 1492–1496 | DOI: 10.1183/13993003.00890-2016 | Copyright ©ERS 2016

# Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study



To the Editor:

Russia has the third highest absolute number of multidrug-resistant (MDR) tuberculosis (TB) cases in the world [1], yet little is known about the scale of childhood MDR-TB in the country; available publications are limited to small case series in older children [2, 3]. Successful treatment outcomes for children with MDR-TB vary widely in other settings, ranging from 53% to 97% [4].

The Arkhangelsk region has one of the highest rates of MDR-TB in Russia [5]. The first paediatric MDR-TB case was registered in 2001. The Arkhangelsk Regional Tuberculosis Dispensary, a state healthcare tertiary TB centre, coordinates care for all patients with drug-resistant TB in the region and works closely with two paediatric sanatoriums.

We conducted a retrospective cohort study of all children (<18 years) diagnosed with MDR-TB in the region, from January 1, 2001 to December 31, 2012 with follow-up data to December 31, 2015. Data were extracted from patient health records and treatment cards. In the Russian national TB programme, childhood TB is disaggregated into younger children (<15 years) and adolescents (15–18 years). This cut-off was preserved to align with country reporting.

MDR-TB was considered as confirmed or clinically-diagnosed. Confirmed cases were verified by culture and drug-sensitivity testing and/or molecular testing. Clinically diagnosed cases were defined according to published consensus definitions [6] and TB severity was categorised based on established criteria [7]. Children with sputum smear- or culture-positive MDR-TB were treated as in-patients at the dispensary until they were considered non-infectious; most sputum culture-negative cases were treated in the paediatric sanatoriums. A few children were managed at home with directly observed therapy (DOT).

Tuberculin skin testing (TST) was performed at baseline and repeated at 6 weeks if initially negative. Toxicity monitoring included full blood count, blood biochemistry, urinalysis, thyroid stimulating hormone (TSH) and hearing evaluation. Children aged  $\geq 4$  years treated in the dispensary underwent pure-tone audiometry; all children aged  $< 4$  years and children treated in sanatoriums had whispered voice testing administered by trained clinicians. Patients treated with ethambutol underwent monthly ophthalmology review. Other paediatric specialists (endocrinologists, nephrologists and psychologists) reviewed children as required.

Treatment outcomes were classified as per World Health Organization (WHO) definitions [8]. Comparisons between baseline characteristics in the two age groups were made using Fisher's exact test for categorical variables and Wilcoxon's rank-sum (Mann-Whitney) test for continuous variables, and unadjusted Poisson regression was used to compare the number of grade 3–4 events. Statistical analyses were performed with Stata version 14.0 (StataCorp LP, College Station, TX, USA). Written informed consent was obtained from the children's families at the time of MDR-TB diagnosis. The study received research ethics approval from the Northern State Medical University (Arkhangelsk, Russia).

Over the study period, the TB incidence rate in children decreased from 12–15 per 100 000 population in 2001–2009 to 7–9 per 100 000 in 2010–2012; the proportion of MDR cases ranged from 4.9 to 42%. Overall, of 366 children diagnosed with TB, 56 (15%) were MDR. Clinical and treatment characteristics were available for 52 children. The median age at diagnosis was 10.6 years (interquartile range (IQR) 5.0–15.9). Overall, in 48 (92%) children an adult source case with MDR-TB was identified; 33 (63%) children were diagnosed following contact screening. 28 (54%) children were asymptomatic and 41 (79%) had TST induration  $\geq 10$  mm. 28 (54%) children had pulmonary TB and seven had cavities. All children were tested for HIV; none were positive. 17 (33%) children had confirmed MDR-TB: 16 had positive culture, including one child with XDR-TB, and one was confirmed by nucleic acid amplification test (GenoTypeMTBDRplus; Hain Lifescience, Nehren, Germany) only. Nine (17%) had severe TB at diagnosis (table 1).

Most children were treated in hospital or sanatoriums; only three had full treatment at home. Overall median treatment duration was 21.7 months (IQR 17.0–24.0). Treatment regimens were constructed based on the existing WHO recommendations. Younger children received a shorter duration of injectable drugs compared to adolescents ( $p < 0.001$ ) (table 1).

Adverse reactions were experienced by 25 (48%) children. Eight children had 10 moderate-to-severe reactions (five raised transaminases, five eosinophilia), with temporary treatment interruption in four (three drug-induced hepatitis, one severe eosinophilia). One child had treatment discontinuation due to mild renal toxicity. Nausea and/or vomiting were observed in five (13%) out of 40 children treated with prothionamide. 20 (38%) children developed increased liver transaminases. TSH elevation was observed in 15 children treated with prothionamide and/or para-aminosalicylic acid (15 (31%) out of 48); all remained asymptomatic and received levothyroxine until MDR-TB treatment completion. Two (5%) out of 41 children on cycloserine had emotional lability and irritability. Four (8%) out of 52 children complained of persistent knee joint pain; one had elevated uric acid and received allopurinol. One of 26 children tested by pure-tone audiometry had mild hearing loss. All other children were tested by whispered voice; they had no clinically significant hearing loss during follow-up.

All 52 children were followed up for at least 18 months post-treatment; none were lost to follow-up. 47 (90%) had successful outcomes (16 achieved cure and 31 completed treatment). Three children did not complete treatment: one stopped after 3.7 months for drug-related nephrotoxicity and two adolescents discontinued at 7.7 and 12.4 months. All three were sputum smear/culture-negative and improved despite premature treatment discontinuation. One child relapsed; she subsequently completed a 14-month re-treatment regimen without recurrence. One patient, diagnosed at age 13 years with sputum smear/culture-positive MDR-TB, resistant to all first-line drugs and ethionamide, died at age 21 years from extensive pulmonary TB.

Most children (63%) were identified through contact screening. In contrast to other contexts with high rates of TB in children aged less than 5 years [9], our data show a relatively low proportion of the caseload in this age group. This is consistent with another study from Pakistan which demonstrated that children aged over 5 years had similar rates of MDR-TB to younger children [10]. Over half of the children were asymptomatic with only radiological manifestations at diagnosis, and two-thirds had clinically-diagnosed MDR-TB. The findings suggest that contact tracing and subsequent close follow-up allowed early diagnosis of MDR-TB; the decision to treat children with symptoms suggestive of TB and contact history without bacteriological confirmation allowed for timely treatment initiation.

Successful outcomes were achieved in 90% of children. Younger children had predominantly non-severe TB and a shorter duration of injectable treatment. This is consistent with other paediatric studies [4, 11, 12].

TABLE 1 Multidrug-resistant (MDR) tuberculosis (TB) in children in the Arkhangelsk region, Russia: baseline characteristics at diagnosis, treatment duration and outcome

	Children aged <15 years at diagnosis	Adolescents aged 15–18 years at diagnosis	Overall	p-value
<b>Patients n</b>	36	16	52	
<b>Age at diagnosis of MDR-TB disease years</b>	7.0 (4.1–10.9)	16.6 (15.9–17.2)	10.6 (5.0–15.9)	NA
<b>Male sex</b>	13 (36)	8 (50)	21 (40)	0.3753
<b>Methods of case finding</b>				0.2203
Contact tracing	25 (69)	8 (50)	33 (63)	
Annual routine TST screening <sup>#</sup>	6 (17)	3 (19)	9 (17)	
Fluorography screening <sup>#</sup>	0	3 (19)	3 (4)	
Presented with symptoms	5 (14)	2 (13)	7 (13)	
<b>Identified source case with MDR-TB</b>	32 (89)	16 (100)	48 (92)	0.2988
<b>TST</b>				0.2377
<5 mm	5 (14)	0	5 (10)	
5–10 mm	3 (8)	3 (18)	6 (12)	
≥10 mm	28 (78)	13 (81)	41 (79)	
<b>Type of MDR-TB</b>				0.0001 <sup>f</sup>
Pulmonary only	5 (14)	12 (75)	17 (33)	
Extrapulmonary only	21 (58)	3 (19)	24 (46)	
Pulmonary and extrapulmonary	10 (28)	1 (6)	11 (21)	
<b>Presenting symptoms</b>				0.0384
TB-related symptoms <sup>¶</sup>	13 (36)	11 (69)	24 (46)	
Asymptomatic	23 (64)	5 (31)	28 (54)	
<b>Microbiological confirmation</b>				0.3400
Positive culture or NAAT	10 (28)	7 (44)	17 (33)	
<b>Severity of disease</b>				0.1132
Severe	4 (11)	5 (31)	9 (17)	
Non-severe	32 (89)	11 (69)	43 (83)	
<b>Treatment duration months</b>				
Duration of hospital admission	3.0 (2.7–6.3), 5 patients	4.5 (3.0–5.5), 10 patients	4.1 (3.0–5.7), 15 patients	0.8065
Duration of sanatorium treatment	18.1 (14.9–22.6), 31 patients	8.2 (6.7–12.3), 5 patients	17.6 (12.6–22.1), 36 patients	0.0163
Duration of treatment	20.8 (16.4–22.8)	22.8 (19.2–26.4)	21.7 (17.0–24.0)	0.1268
Duration of treatment with injectables <sup>*</sup>	4.3 (3.0–6.1), 33 patients	7.6 (6.2–9.3), 16 patients	5.9 (3.3–7.4), 49 patients	0.0002
<b>Grade 3–4 adverse reactions<sup>§</sup> n</b>				0.5299 <sup>##</sup>
Patients experiencing adverse events	5	3	8	
Total adverse events	6	4	10	
Elevated ALT and/or AST	4	1	5	
Eosinophilia (asymptomatic)	2	3	5	
<b>Outcome</b>				0.6374 <sup>¶¶</sup>
Favourable outcome	33 (92)	14 (88)	47 (90)	
Cure n	9	7	16	
Treatment completed n	24	7	31	
Unfavourable outcome	3 (8)	2 (13)	5 (10)	
Relapse or recurrence of MDR-TB n	1	0	1	
Treatment incomplete n	1	2	3	
Treatment failed, died n	1	0	1	

Data are presented as median (interquartile range) or n (%), unless otherwise stated. Where data were not available for the whole cohort, the number of patients for which the data were available is shown. TST: tuberculin skin test; NAAT: nucleic acid amplification tests; ALT: alanine aminotransferase; AST: aspartate aminotransferase; NA: not applicable. <sup>#</sup>: part of routine TB screening in Russia, annual TST in all children and two yearly fluorography in children aged 15–18 years; <sup>¶</sup>: cough, fever, weight loss of any duration; <sup>\*</sup>: three children were not treated with injectables: two had TB nephritis, and the third had disease caused by *Mycobacterium tuberculosis* resistant to both capreomycin and kanamycin; <sup>§</sup>: grading of the adverse reactions adapted from Division of Microbiology and Infectious Diseases (DMID) paediatric toxicity tables, 2007; <sup>f</sup>: comparison between pulmonary only TB and other forms; <sup>##</sup>: comparison of number of events; <sup>¶¶</sup>: comparison between favourable and unfavourable outcomes.

Our study showed high rates of successful treatment in adolescents in contrast to other recent studies reporting poor outcomes in this age group [13, 14]. Daily DOT administered by medical personnel may well have contributed to this. Although nearly half of the children experienced adverse reactions, most were actively managed, allowing continuation of the prescribed regimen in most children.

This study has limitations of retrospective design and suboptimal hearing assessment in most children, therefore, the hearing loss was likely to be underestimated.

The treatment of MDR-TB in children is complex, challenging, of long duration, and is associated with high rates of adverse reactions. Improved regimens are urgently needed and the new drugs, bedaquiline and delamanid, could play a more prominent role in paediatric MDR-TB treatment [15, 16]. In spite of this, however, treatment success was achieved in most children with a proactive approach to contact tracing, early treatment based on clinical diagnosis, structured approach to the construction of drug regimens based on the international recommendations, and the active management of adverse reactions.



@ERSpublications

**High proportion of children with MDR-TB had favourable outcome (90%) with early diagnosis and treatment initiation** <http://ow.ly/2eq5302gWmr>

Polina A. Smirnova<sup>1,5</sup>, Anna Turkova<sup>2,5</sup>, Elena I. Nikishova<sup>3</sup>, James A. Seddon<sup>4</sup>, Elizabeth Chappell<sup>2</sup>, Olga A. Zolotaya<sup>1</sup>, Oxana M. Mironuk<sup>1</sup> and Andrey O. Maryandyshev<sup>3</sup>

<sup>1</sup>Child and Adolescent Specialised Centre, Arkhangelsk Regional Tuberculosis Dispensary, Arkhangelsk, Russian Federation. <sup>2</sup>MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK. <sup>3</sup>Dept of Phthisiopulmonology, Northern State Medical University, Arkhangelsk, Russian Federation. <sup>4</sup>Dept of Academic Paediatrics, Imperial College London, London, UK. <sup>5</sup>Both authors contributed equally.

Correspondence: Anna Turkova, MRC Clinical Trials Unit, University College London, Aviation House, 125 Kingsway, London WC2B 6NH, UK. E-mail: a.turkova@ucl.ac.uk

Received: Nov 25 2015 | Accepted after revision: July 06 2016 | First published online: Sept 1 2016

Conflict of interest: None declared.

Acknowledgements: We thank all the staff of the Arkhangelsk Regional Tuberculosis Dispensary, and children and their parents who made this study possible.

## References

- 1 World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB/2014.08. Geneva, World Health Organization, 2014. Available from [www.who.int/tb/publications/global\\_report/gtbr14\\_main\\_text.pdf](http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf). Date last accessed: November 21, 2015.
- 2 Firsova V, Poluektova F, Ryzhova A. Primary drug resistance of *M. tuberculosis* in teenagers with tuberculosis: clinical peculiarities, effectiveness of treatment. *Probl Tuberc Lung Dis* 2008; 5: 28–30.
- 3 Panova L, Ovsyankina E. Treatment and treatment outcomes of MDR-TB in children and adolescents. *Probl Tuberc Lung Dis* 2007; 5: 20–21.
- 4 Ettehad D, Schaaf HS, Seddon JA, *et al*. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis* 2012; 12: 449–456.
- 5 Eliseev PI, Maryandyshev AO, Nikishova EI, *et al*. Epidemiological analyses of tuberculosis in Archangelsk, Russia and implementation of a rapid assay for detection of resistance in this high burden setting. *Int J Mycobacteriol* 2013; 2: 103–108.
- 6 Seddon JA, Perez-Velez CM, Schaaf HS, *et al*. Consensus statement on research definitions for drug-resistant tuberculosis in children. *J Pediatric Infect Dis Soc* 2013; 2: 100–109.
- 7 Wiseman CA, Gie RP, Starke JR, *et al*. A proposed comprehensive classification of tuberculosis disease severity in children. *Pediatr Infect Dis J* 2012; 31: 347–352.
- 8 World Health Organization. Definitions and reporting framework for tuberculosis: 2013 revision (updated December 2014). WHO/HTM/TB/2013.2. Geneva, World Health Organization, 2013. Available from [http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf). Date last accessed: November 21, 2015.
- 9 Harries AD, Hargreaves NJ, Graham SM, *et al*. Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes. *Int J Tuberc Lung Dis* 2002; 6: 424–431.
- 10 Amanullah F, Ashfaq M, Khowaja S, *et al*. High tuberculosis prevalence in children exposed at home to drug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2014; 18: 520–527.
- 11 Seddon JA, Hesselting AC, Willemsse M, *et al*. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. *Clin Infect Dis* 2012; 54: 157–166.
- 12 Seddon JA, Hesselting AC, Godfrey-Faussett P, *et al*. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. *Thorax* 2014; 69: 458–464.
- 13 Moyo S, Furin JJ, Hughes J, *et al*. Outcomes in adolescents undergoing treatment for drug-resistant tuberculosis in Cape Town, South Africa, 2008–2013. *Arch Pediatr Infect Dis* 2014; 3: e17934.
- 14 Isaakidis P, Das M, Saranchuk P. Outcomes in adolescents undergoing treatment for drug-resistant tuberculosis in Mumbai. *Arch Pediatr Infect Dis* 2015; 3: e30400.
- 15 Esposito S, D'Ambrosio L, Tadolini M, *et al*. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. *Eur Respir J* 2014; 44: 811–815.
- 16 Tadolini M, Garcia-Prats AJ, D'Ambrosio L, *et al*. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. *Eur Respir J* 2016; 48: 938–943.